import { Drug } from '@/types';

export const antidepressantsData: Drug[] = [
  {
    id: 'sertraline',
    name: 'Sertraline',
    class: 'SSRI',
    mechanism: 'Selective serotonin reuptake inhibitor (SSRI). Blocks serotonin reuptake at the presynaptic neuron, increasing serotonin availability in the synaptic cleft.',
    indications: [
      'Major depressive disorder (MDD)',
      'Obsessive-compulsive disorder (OCD)',
      'Panic disorder',
      'Post-traumatic stress disorder (PTSD)',
      'Social anxiety disorder',
      'Premenstrual dysphoric disorder (PMDD)',
    ],
    contraindications: [
      'Concurrent MAOI use (within 14 days)',
      'Concurrent pimozide use',
      'Hypersensitivity to sertraline',
    ],
    sideEffects: [
      'Gastrointestinal upset (nausea, diarrhea)',
      'Sexual dysfunction (decreased libido, anorgasmia)',
      'Insomnia or somnolence',
      'Activation/restlessness (early treatment)',
      'Weight changes',
      'Headache',
      'Diaphoresis',
    ],
    interactions: [
      'MAOIs: Risk of serotonin syndrome',
      'NSAIDs/anticoagulants: Increased bleeding risk',
      'Other serotonergic drugs: Additive serotonin effects',
      'CYP2D6 substrates: Mild inhibition',
    ],
    monitoring: [
      'Mood and suicidal ideation (especially in youth)',
      'Activation/agitation symptoms',
      'Sexual side effects',
      'Weight',
    ],
    dosing: {
      starting: '25-50 mg daily',
      therapeutic: '50-200 mg daily',
      maximum: '200 mg daily',
    },
    switchingNotes: [
      'Cross-taper when switching to SNRIs',
      'Direct switch possible to most SSRIs',
      'Requires washout before MAOI (minimum 14 days)',
    ],
    warnings: [
      'Black box warning: Increased suicidal thinking in children, adolescents, and young adults',
      'Serotonin syndrome risk when combined with other serotonergic agents',
      'Activation in early treatment may increase agitation',
    ],
    specialPopulations: {
      pregnancy: 'Category C. Weigh risks/benefits; third trimester exposure may cause neonatal complications.',
      lactation: 'Excreted in breast milk; generally considered compatible with caution.',
      geriatric: 'Start at lower doses; increased risk of hyponatremia (SIADH).',
      renal: 'No dose adjustment typically needed.',
      hepatic: 'Use lower doses or less frequent dosing in severe impairment.',
    },
  },
  {
    id: 'fluoxetine',
    name: 'Fluoxetine',
    class: 'SSRI',
    mechanism: 'Selective serotonin reuptake inhibitor with longest half-life among SSRIs. Active metabolite (norfluoxetine) extends duration of action.',
    indications: [
      'Major depressive disorder',
      'OCD',
      'Panic disorder',
      'Bulimia nervosa',
      'PMDD',
    ],
    contraindications: [
      'Concurrent MAOI use (within 14 days; 5 weeks washout required before MAOI)',
      'Concurrent pimozide or thioridazine',
    ],
    sideEffects: [
      'GI upset',
      'Sexual dysfunction',
      'Insomnia',
      'Activation',
      'Headache',
      'Anxiety',
    ],
    interactions: [
      'Strong CYP2D6 inhibitor: many drug interactions',
      'MAOIs: Serotonin syndrome risk',
      'Tamoxifen: Reduced efficacy',
    ],
    monitoring: [
      'Mood and suicidality',
      'Activation symptoms',
      'Weight',
    ],
    dosing: {
      starting: '10-20 mg daily',
      therapeutic: '20-60 mg daily',
      maximum: '80 mg daily',
    },
    switchingNotes: [
      'Long half-life (4-6 days for fluoxetine, 4-16 days for norfluoxetine) simplifies discontinuation',
      'Requires 5-week washout before starting MAOI',
      'Direct switch to most other antidepressants possible after washout',
    ],
    warnings: [
      'Black box: Suicidal ideation in youth',
      'Long half-life may delay onset of action and clearance',
      'Strong CYP2D6 inhibitor affects many medications',
    ],
    specialPopulations: {
      pregnancy: 'Category C. Weigh risks/benefits.',
      lactation: 'Present in breast milk; use with caution.',
      geriatric: 'Lower starting doses; SIADH risk.',
      renal: 'No adjustment typically needed.',
      hepatic: 'Lower doses or extended intervals in cirrhosis.',
    },
  },
  {
    id: 'escitalopram',
    name: 'Escitalopram',
    class: 'SSRI',
    mechanism: 'S-enantiomer of citalopram. Highly selective serotonin reuptake inhibitor with minimal CYP interactions.',
    indications: [
      'Major depressive disorder',
      'Generalized anxiety disorder',
    ],
    contraindications: [
      'Concurrent MAOI use',
      'Concurrent pimozide',
      'Known QT prolongation or use with QT-prolonging drugs at higher doses',
    ],
    sideEffects: [
      'GI upset',
      'Sexual dysfunction',
      'Insomnia or somnolence',
      'Fatigue',
      'Increased sweating',
    ],
    interactions: [
      'MAOIs: Serotonin syndrome',
      'QT prolongation at doses >20 mg/day',
      'Minimal CYP interactions',
    ],
    monitoring: [
      'Mood and suicidality',
      'QT interval if dose >20 mg or risk factors present',
    ],
    dosing: {
      starting: '10 mg daily',
      therapeutic: '10-20 mg daily',
      maximum: '20 mg daily',
    },
    switchingNotes: [
      'Direct switch to other SSRIs generally safe',
      'Cross-taper with SNRIs',
      'Washout required before MAOI',
    ],
    warnings: [
      'Black box: Suicidality in youth',
      'QT prolongation risk at doses >20 mg',
      'May prolong QT in vulnerable patients',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; use with caution.',
      geriatric: '10 mg recommended maximum dose.',
      renal: 'No adjustment for mild-moderate impairment.',
      hepatic: '10 mg maximum in hepatic impairment.',
    },
  },
  {
    id: 'venlafaxine',
    name: 'Venlafaxine',
    class: 'SNRI',
    mechanism: 'Serotonin-norepinephrine reuptake inhibitor. At lower doses primarily inhibits serotonin reuptake; norepinephrine reuptake inhibition increases at higher doses.',
    indications: [
      'Major depressive disorder',
      'Generalized anxiety disorder',
      'Social anxiety disorder',
      'Panic disorder',
    ],
    contraindications: [
      'Concurrent MAOI use',
      'Uncontrolled hypertension (relative)',
    ],
    sideEffects: [
      'Nausea',
      'Sexual dysfunction',
      'Increased blood pressure (dose-dependent)',
      'Sweating',
      'Insomnia',
      'Dizziness',
      'Discontinuation syndrome if abruptly stopped',
    ],
    interactions: [
      'MAOIs: Serotonin syndrome',
      'CYP2D6 substrate',
    ],
    monitoring: [
      'Blood pressure (especially at higher doses)',
      'Mood and suicidality',
      'Discontinuation symptoms',
    ],
    dosing: {
      starting: '37.5-75 mg daily (extended release)',
      therapeutic: '75-225 mg daily',
      maximum: '225 mg daily (up to 375 mg in some cases)',
    },
    switchingNotes: [
      'Must taper slowly due to short half-life and discontinuation syndrome',
      'Cross-taper when switching to/from other antidepressants',
      'Washout required before MAOI',
    ],
    warnings: [
      'Black box: Suicidality in youth',
      'Dose-dependent blood pressure elevation',
      'Severe discontinuation syndrome if stopped abruptly',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Present in milk; weigh risks/benefits.',
      geriatric: 'Monitor blood pressure closely.',
      renal: 'Reduce dose by 25-50% in renal impairment.',
      hepatic: 'Reduce dose by 50% in moderate-severe impairment.',
    },
  },
  {
    id: 'duloxetine',
    name: 'Duloxetine',
    class: 'SNRI',
    mechanism: 'Balanced serotonin-norepinephrine reuptake inhibitor. Also used for pain conditions due to noradrenergic effects.',
    indications: [
      'Major depressive disorder',
      'Generalized anxiety disorder',
      'Diabetic peripheral neuropathy',
      'Fibromyalgia',
      'Chronic musculoskeletal pain',
    ],
    contraindications: [
      'Concurrent MAOI use',
      'Uncontrolled narrow-angle glaucoma',
      'Severe hepatic impairment',
    ],
    sideEffects: [
      'Nausea',
      'Dry mouth',
      'Constipation',
      'Somnolence',
      'Dizziness',
      'Increased sweating',
      'Sexual dysfunction',
    ],
    interactions: [
      'MAOIs: Serotonin syndrome',
      'CYP1A2 and CYP2D6 substrate',
      'Avoid with alcohol (hepatotoxicity risk)',
    ],
    monitoring: [
      'Liver function tests if hepatic concerns',
      'Blood pressure',
      'Mood and suicidality',
    ],
    dosing: {
      starting: '30 mg daily',
      therapeutic: '60 mg daily',
      maximum: '120 mg daily',
    },
    switchingNotes: [
      'Taper to minimize discontinuation symptoms',
      'Cross-taper recommended',
      'Washout before MAOI',
    ],
    warnings: [
      'Black box: Suicidality',
      'Hepatotoxicity risk; avoid in severe liver disease',
      'Not recommended with substantial alcohol use',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; caution advised.',
      geriatric: 'Start low; monitor blood pressure and falls risk.',
      renal: 'Avoid in severe renal impairment (CrCl <30).',
      hepatic: 'Contraindicated in severe hepatic impairment.',
    },
  },
  {
    id: 'bupropion',
    name: 'Bupropion',
    class: 'Atypical Antidepressant (NDRI)',
    mechanism: 'Norepinephrine-dopamine reuptake inhibitor. Does not affect serotonin. Also used for smoking cessation.',
    indications: [
      'Major depressive disorder',
      'Seasonal affective disorder',
      'Smoking cessation (as Zyban)',
      'Adjunct for ADHD (off-label)',
    ],
    contraindications: [
      'Seizure disorder or history of seizures',
      'Eating disorders (anorexia/bulimia)',
      'Abrupt discontinuation of alcohol or sedatives',
      'MAOI use within 14 days',
    ],
    sideEffects: [
      'Insomnia',
      'Agitation/anxiety',
      'Headache',
      'Dry mouth',
      'Nausea',
      'Weight loss',
      'Tremor',
      'NO sexual side effects (beneficial)',
    ],
    interactions: [
      'CYP2D6 inhibitor',
      'Lowers seizure threshold',
      'Avoid with MAOIs',
    ],
    monitoring: [
      'Seizure risk factors',
      'Blood pressure',
      'Mood and suicidality',
      'Weight',
    ],
    dosing: {
      starting: '150 mg daily (SR or XL)',
      therapeutic: '300 mg daily',
      maximum: '450 mg daily (divided doses for IR/SR)',
    },
    switchingNotes: [
      'Can be combined with SSRIs/SNRIs to mitigate sexual side effects',
      'Direct switch generally safe',
      'Washout before MAOI',
    ],
    warnings: [
      'Black box: Suicidality and neuropsychiatric events (smoking cessation)',
      'Dose-dependent seizure risk (highest with IR formulation)',
      'Contraindicated in eating disorders due to seizure risk',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Present in milk; weigh risks/benefits.',
      geriatric: 'Lower starting doses; monitor for agitation.',
      renal: 'Reduce dose in severe impairment.',
      hepatic: 'Reduce dose; max 150 mg QD in severe impairment.',
    },
  },
  {
    id: 'mirtazapine',
    name: 'Mirtazapine',
    class: 'Atypical Antidepressant (NaSSA)',
    mechanism: 'Noradrenergic and specific serotonergic antidepressant. Alpha-2 antagonist increasing NE and 5-HT release. Also blocks 5-HT2 and 5-HT3 receptors. Strong H1 antagonist causing sedation.',
    indications: [
      'Major depressive disorder',
      'Off-label: insomnia, appetite stimulation',
    ],
    contraindications: [
      'Concurrent MAOI use',
    ],
    sideEffects: [
      'Sedation (especially at lower doses)',
      'Increased appetite and weight gain',
      'Dry mouth',
      'Constipation',
      'Dizziness',
      'Rare: agranulocytosis',
    ],
    interactions: [
      'MAOIs: Serotonin syndrome',
      'CNS depressants: Additive sedation',
    ],
    monitoring: [
      'Weight',
      'Sedation level',
      'Mood and suicidality',
      'CBC if signs of infection (agranulocytosis risk)',
    ],
    dosing: {
      starting: '15 mg at bedtime',
      therapeutic: '15-45 mg at bedtime',
      maximum: '45 mg daily',
    },
    switchingNotes: [
      'Can be used to augment SSRIs/SNRIs (California rocket fuel with venlafaxine)',
      'Direct switch or cross-taper',
      'Washout before MAOI',
    ],
    warnings: [
      'Black box: Suicidality',
      'Paradoxically more sedating at lower doses (H1 antagonism)',
      'Rare but serious: agranulocytosis',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; use with caution.',
      geriatric: 'Lower doses; monitor for orthostatic hypotension.',
      renal: 'Caution in severe impairment.',
      hepatic: 'Caution in hepatic impairment.',
    },
  },
  {
    id: 'amitriptyline',
    name: 'Amitriptyline',
    class: 'Tricyclic Antidepressant (TCA)',
    mechanism: 'Inhibits reuptake of both serotonin and norepinephrine. Also blocks histamine, muscarinic, and alpha-1 receptors (causing many side effects).',
    indications: [
      'Major depressive disorder (less commonly used now)',
      'Chronic pain (neuropathic pain, migraine prophylaxis)',
    ],
    contraindications: [
      'Recent MI',
      'Concurrent MAOI use',
      'Narrow-angle glaucoma',
      'Urinary retention',
    ],
    sideEffects: [
      'Anticholinergic: dry mouth, constipation, urinary retention, blurred vision',
      'Sedation',
      'Orthostatic hypotension',
      'Weight gain',
      'Cardiac conduction delays',
      'Sexual dysfunction',
    ],
    interactions: [
      'MAOIs: Hypertensive crisis',
      'CYP2D6 substrate',
      'QT prolongation risk',
    ],
    monitoring: [
      'ECG (especially in elderly or cardiac disease)',
      'Blood pressure',
      'Anticholinergic side effects',
    ],
    dosing: {
      starting: '25 mg at bedtime',
      therapeutic: '75-150 mg daily (depression); 10-75 mg (pain)',
      maximum: '300 mg daily',
    },
    switchingNotes: [
      'Taper slowly',
      'Long washout before MAOI (14 days)',
      'Generally switched to SSRIs/SNRIs due to better tolerability',
    ],
    warnings: [
      'Black box: Suicidality',
      'Lethal in overdose (cardiotoxic)',
      'Anticholinergic burden in elderly',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; use caution.',
      geriatric: 'Avoid or use very low doses (Beers Criteria); high fall/delirium risk.',
      renal: 'Caution.',
      hepatic: 'Use lower doses.',
    },
  },
  {
    id: 'phenelzine',
    name: 'Phenelzine',
    class: 'MAOI (Monoamine Oxidase Inhibitor)',
    mechanism: 'Irreversibly inhibits monoamine oxidase (MAO-A and MAO-B), preventing breakdown of serotonin, norepinephrine, and dopamine.',
    indications: [
      'Treatment-resistant depression',
      'Atypical depression',
    ],
    contraindications: [
      'Concurrent use of SSRIs, SNRIs, TCAs, other MAOIs',
      'Pheochromocytoma',
      'Cardiovascular disease',
      'Foods high in tyramine',
    ],
    sideEffects: [
      'Orthostatic hypotension',
      'Weight gain',
      'Sexual dysfunction',
      'Insomnia',
      'Hypertensive crisis with tyramine',
    ],
    interactions: [
      'Serotonergic drugs: Serotonin syndrome',
      'Sympathomimetics: Hypertensive crisis',
      'Tyramine-rich foods: Hypertensive crisis',
    ],
    monitoring: [
      'Blood pressure (orthostatic vitals)',
      'Dietary compliance (low-tyramine diet)',
    ],
    dosing: {
      starting: '15 mg TID',
      therapeutic: '45-90 mg daily in divided doses',
      maximum: '90 mg daily',
    },
    switchingNotes: [
      'Requires extensive washout: 14 days from most antidepressants, 5 weeks from fluoxetine',
      '14-day washout required before starting another antidepressant',
      'High risk of serotonin syndrome if washout inadequate',
    ],
    warnings: [
      'Black box: Suicidality',
      'Hypertensive crisis with tyramine ingestion or sympathomimetics',
      'Dietary restrictions required (aged cheeses, cured meats, draft beer, etc.)',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Avoid.',
      geriatric: 'High fall risk due to orthostatic hypotension.',
      renal: 'Caution.',
      hepatic: 'Contraindicated in hepatic impairment.',
    },
  },
];
